Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis

Background: Natalizumab (NTZ) is a monoclonal antibody with an immunosuppressive effect that reduces the inflammation of the central nervous system, and it has been used for the treatment of relapsing-remitting multiple sclerosis (RRMS). In patients with low cellular immune response, systemic mycosi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2018-06, Vol.24 (7), p.1002-1004
Hauptverfasser:	Almeida, Kelson James, Barreto-Soares, Raissa Viera, Campos-Sousa, Raimundo Nonato, Campos-Sousa, Maria Graças, Bor-Seng-Shu, Edson
Format:	Artikel
Sprache:	eng
Schlagworte:	Central nervous system Humans Immune response Immune response (cell-mediated) Immunocompromised Host Immunologic Factors - adverse effects Immunosuppression Immunotherapy Interferon Lung Diseases, Fungal - immunology Male Middle Aged Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Mycosis Natalizumab - adverse effects Paracoccidioidomycosis - immunology Patients South American blastomycosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!